Novocure spikes 30% after drug trial met primary endpoint

Shares of oncology drug maker Novocure spiked over 30% after the company reported that its METIS Phase 3 clinical trial met the primary endpoint in its NSCLC study. Shares of Novocure were up approximately 31% or almost $4 per share to more than $17 in pre-market on Wednesday.